Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Treatment for Pompe Disease Biotech Investing
CymaBay Announces the Appointments of Robert Booth and Caroline Loewy to Its Board of Directors Pharmaceutical Investing
UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis Pharmaceutical Investing
Horizon Pharma Announces Topline Results from Phase 3 Study of ACTIMMUNE in Friedreich's Ataxia Pharmaceutical Investing
Catalyst Pharmaceuticals Provides Update on Clinical Trial for Patients with Congenital Myasthenic Syndromes Pharmaceutical Investing
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Drug Candidate for Ulcerative Colitis Pharmaceutical Investing
CymaBay Therapeutics Announces the Initiation of Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis Pharmaceutical Investing
XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer Biotech Investing
International Stem Cell Corporation Announces Second Patient with Parkinson’s Disease Treated in Phase I Clinical Trial Genetics Investing
Kitov Successfully Completes All KIT-302 Testing Required for New Drug Application to US FDA Pharmaceutical Investing
Reata Pharmaceuticals Announces Filing of Registration Statement for Proposed Public Offering Biotech Investing
